Demo Brand Opens New Research Facility in Singapore

December 3, 2024 · 4 min read

We are proud to announce the opening of our newest research and development center in Singapore, marking our largest investment in the Asia-Pacific region to date.

The 12,000 square meter facility, located in Biopolis, will house 340 scientists and researchers specializing in oncology and immunotherapy. Construction began in March 2022, and the project was completed three months ahead of schedule at a total cost of S$180 million.

“Singapore represents a strategic hub for innovation,” said Dr. Helena Lindqvist, Chief Scientific Officer. “By 2027, we expect this facility to contribute to at least 15 new drug candidates entering clinical trials.”

The center will collaborate closely with the National University of Singapore and Nanyang Technological University, building on existing partnerships established in 2019. Initial focus areas include CAR-T cell therapy and next-generation antibody development.

This expansion brings our global research footprint to 8 dedicated facilities across Germany, the United States, Japan, Brazil, and now Singapore.